First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

Jiaxin Niu, Corinne Maurice‐Dror, D.H. Lee, +16

Annals of Oncology

Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Alexander Muik, Elena Garralda, Friederike Gieseke, +34

Cancer Discovery

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

Nicolette M. Fonseca, Corinne Maurice‐Dror, Cameron Herberts, +36

Nature Communications

A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.

Manish R. Patel, Todd M. Bauer, Antonio Jimeno, +14

Journal of Clinical Oncology

ImmunologyImmune RegulationPathologyImmunoeditingImmunotherapeutics +21

LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.

Carlos Gomez‐Roca, Eduardo Yáñez, Seock‐Ah Im, +13

Journal of Clinical Oncology

OncologyCancer EpidemiologyPd-l1 ExpressionImmunologyTumor Immunity +10

Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.

Luis J. Villanueva-Rivera, Zarnie Lwin, Hyun Cheol Chung, +17

Journal of Clinical Oncology

Biliary Tract CancersAdvanced BtcPd-l1 ExpressionGastrointestinal OncologyMedicine +12

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

Martin Sjöström, Shuang G. Zhao, Samuel Levy, +61

Cancer Research

A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer

Corinne Maurice‐Dror, Ronan Le Moigne, Ulka N. Vaishampayan, +6

Investigational New Drugs

UrologyOncologyMedicinePharmacotherapyAnti-cancer Agent +5

1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC

M-J. Ahn, Jiaxin Niu, Dongwook Kim, +12

Annals of Oncology

Anti-tigit AntibodyMedicineImmunologyTherapeutic EfficacyImmune Checkpoint Inhibitor +5

Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study.

Luis J. Villanueva-Rivera, Zarnie Lwin, Hyun Cheol Chung, +17

Journal of Clinical Oncology

Biliary Tract CancersCancer ManagementImmunologyPathologyMulticohort Phase 2 +14